Topics

EU Restricts High-Dose Cyproterone Because of Meningioma Risk

06:52 EST 14 Feb 2020 | Medscape

Products containing the antiandrogen cyproterone with daily doses of 10 mg or more should be restricted because of a risk of meningioma.
News Alerts

Original Article: EU Restricts High-Dose Cyproterone Because of Meningioma Risk

NEXT ARTICLE

More From BioPortfolio on "EU Restricts High-Dose Cyproterone Because of Meningioma Risk"

Quick Search